Quanterix Corp, Lexington, Mass, is expanding its single molecule array, or Simoa, portfolio to include the new Quanterix SR-Plex benchtop instrument.
In The News
CLP Magazine | September 26, 2017
Alzforum | September 21, 2017
In this month’s JAMA Neurology, two papers examine whether tau circulating in plasma could offer a blood-based biomarker for brain disorders.
Biocompare | September 19, 2017
Tracking multiple targets in one reaction is an increasing requirement of assays being used in molecular biology and medicine.
Diagnostic World News| August 24, 2017
August 24, 2017 | At the Next Generation Dx Summit* last week, over 100 exhibitors and sponsors shared new technologies, research updates, and their visions for the future of diagnostics. Diagnostics World published a
Biocompare | August 24, 2017
Using an immune-related molecule, usually an antibody, to measure an analyte in a sample makes up the basics of an immunoassay. The best-known version is the enzyme-linked immunosorbent assay (ELISA).
DDN News | August 2017
The study, entitled “Polymerase-free measurement of microRNA-122 with single base specificity using single molecule arrays: Detection of drug-induced liver injury,” is a proof-of-concept paper showing how the scientists combined Quanterix’s Single Molecule Array Detection technology, or Simoa, and…
Modern Life Network: Tech of Sports | August 2, 2017
Quanterix CEO Kevin Hrusovsky sits down with Rick Limpert, host of Tech of Sports by Modern Life Network, to look current concussion detection methods and why many of them fail; and a new test that can dramatically change the game and improve player safety.
Genetic Engineering and Biotechnology News | July 26, 2017
Improved Cancer Immunodiagnostics and Immunotherapeutics Depend on Biomarker Discovery
GenomeWeb| July 18, 2017
NEW YORK (GenomeWeb) – A team of investigators from Quanterix, Destina Genomics, and the University of Edinburgh have developed a new approach for the amplification-free detection of microRNA-122, a biomarker used for diagnosing liver toxicity.
CLP | July 11, 2017
Quanterix Corp, Lexington, Mass, has launched the Simoa Neurology 4-Plex A assay (N4PA).